MetaVia rises after securing global patent protection for obesity drug

MetaVia

13/02/2026 13:55

** Shares of drug developer MetaVia MTVA.O rise 6% to $1.76 premarket

** Co says it has secured broad patent protection for its experimental drug, DA-1726, designed to help people lose weight and improve blood sugar levels in the U.S. and internationally

** The patents, totaling 39 granted and pending, will protect the drug until 2041, with the possibility of further extension, per co

** Co says the drug showed average weight loss of about 9%, reduced waist size, and signs of improved liver health in an early-stage trial

** MTVA plans to begin new studies later this year, testing higher doses and faster treatment schedules, with results expected in the fourth quarter, per co

** Shares down ~62% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))